Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study-Reference-Cited by-同舟云学术

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

Published:2017-06-16 Issue:2 Volume:55 Page:152-160
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Albers Frank C.¹,Müllerová Hana²,Gunsoy Necdet B.³,Shin Ji-Yeon⁴,Nelsen Linda M.⁵,Bradford Eric S.¹,Cockle Sarah M.⁶,Suruki Robert Y.⁷⁸

Affiliation:

1. Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA

2. Real World Evidence, GSK, Stockley Park, Uxbridge, Middlesex, UK

3. Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, UK

4. GSK, Seoul, South Korea

5. Value Evidence and Outcomes, GSK, Collegeville, PA, USA

6. Value Evidence and Outcomes, GSK House, Brentford, Middlesex, UK

7. Worldwide Epidemiology, GSK, Research Triangle Park, NC, USA

8. Department of Epidemiology, UCB Biosciences, Research Triangle Park, NC, USA

Funder

GlaxoSmithKline

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology, and Child Health

Link

https://tandfonline.com/doi/pdf/10.1080/02770903.2017.1322611

Reference23 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

2. Global Initiative for Asthma. 2016 GINA report, global strategy for asthma management and prevention 2016. Available from: http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/[last accessed 19 Jan 2017].

3. Cluster Analysis and Clinical Asthma Phenotypes

4. Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert opinion on diagnosis and management of Severe Asthma in low and middle income countries (LMIC) with focus on India;Journal of Asthma;2024-06-19

2. Direct comparative study of anti-IgE and anti-IL4Rα therapy effectiveness in patients with severe allergic and mixed bronchial asthma;Meditsinskiy sovet = Medical Council;2024-06-06

3. Clinical and allergological characteristics of patients with severe bronchial asthma in the regional registry and phenotyping principles for the targeted therapy choice;Meditsinskiy sovet = Medical Council;2024-06-06

4. Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK;npj Primary Care Respiratory Medicine;2024-05-01

5. Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma;ERJ Open Research;2024-04-11